Psychiatry AtlasMedication guide · United States

Opioid blocker used in alcohol and opioid treatment

Naltrexone (Vivitrol, Revia)

Generic name
naltrexone hydrochloride (oral); naltrexone base in microspheres (Vivitrol)
Brand names
Vivitrol; Revia
Medication class
Opioid blocker used in alcohol and opioid treatment
Forms covered
oral naltrexone hydrochloride tablets; Vivitrol extended-release intramuscular injection

Article updated: 2026-10-24 · Sources last checked: 2026-11-05

Naltrexone is used with counseling and support for alcohol dependence and for opioid blockade or relapse prevention after detoxification. Oral tablets and the monthly Vivitrol injection have different practical and safety instructions.

Revia (discontinued brand).

What to expect: The medicine blocks opioid effects, but recovery is judged over time through drinking or opioid-use outcomes and daily functioning.

Warning signs · Medicine forms
Sources last checked:
2026-11-05

What is this medicine used for?

FDA-approved uses

  • Alcohol dependence — Adults. Used as one part of an addiction treatment plan with counseling and support.oral naltrexone hydrochloride tablets.
  • Alcohol dependence — Adults able to abstain before starting; not actively drinking at first injection. Requires assessment of recent opioid exposure even when the intended treatment is for alcohol use.Vivitrol extended-release intramuscular injection.
  • Blockade of externally administered opioid effects — Adults who are opioid-free after appropriate assessment. This is treatment within an addiction management plan, not reversal of an acute overdose.oral naltrexone hydrochloride tablets.
  • Prevention of relapse to opioid dependence after detoxification — Adults after opioid detoxification. Adequate opioid-free time and clinical assessment are essential before injection.Vivitrol extended-release intramuscular injection.

What should I expect?

The medicine blocks opioid effects, but recovery is judged over time through drinking or opioid-use outcomes and daily functioning. It does not treat alcohol or opioid withdrawal; starting before opioids have cleared can cause severe withdrawal.

Agree on a follow-up plan when treatment starts. Contact the prescriber if symptoms worsen, side effects disrupt daily life, or there is no useful improvement by the planned review; do not change the dose yourself.

How do I take it safely?

Take oral tablets only under the prescribed plan. Vivitrol is administered monthly or every four weeks by a healthcare professional as a deep injection into a buttock muscle; it must not be injected under the skin or into a vein.

Starting or restarting requires assessment of opioid exposure. People previously dependent on short-acting opioids generally need at least 7–10 opioid-free days; vulnerability to withdrawal can last up to two weeks after methadone or buprenorphine. These are not home-start instructions, and tests cannot guarantee that withdrawal will not occur.

Review liver and kidney health, mood, pregnancy plans, upcoming procedures, and pain-treatment needs. Vivitrol also requires review of bleeding risk and whether a safe deep injection is possible. Discuss access to an overdose-reversal medicine such as naloxone.

Current opioid analgesic use, active opioid dependence or acute opioid withdrawal. Positive opioid urine screen or failed naloxone challenge. Allergy to naltrexone or formulation ingredients; Vivitrol also includes polymer and diluent components.

Opioid pain medicines, tramadol, methadone, buprenorphine and some cough or diarrhea products can be blocked or can create withdrawal risk. Tell emergency, surgical and dental clinicians that naltrexone is being used, and carry that information. Pain treatment while blockade is active may require specialist monitoring; never try to overcome it with larger opioid doses. Other potentially liver-damaging medicines also require review.

Pregnancy data are limited, and untreated alcohol or opioid use disorder also carries serious risks. A clinician experienced in addiction and pregnancy should help assess whether to continue or initiate treatment; do not independently stop an effective treatment or switch from another opioid-use-disorder medicine.

The Vivitrol label confirms that naltrexone and 6-beta-naltrexol are present in human milk; infant-effect information remains limited. Breastfeeding needs an individualized discussion. Safety and effectiveness under age 18 are not established for the selected uses. Older adults may need particular attention to renal function and other medicines.

For a missed oral dose, follow the pharmacist’s instructions and do not double the next dose. Contact the clinic promptly about a missed injection. After a treatment gap, opioid exposure must be reassessed before restarting. Naltrexone itself does not cause an opioid withdrawal syndrome on stopping, but loss of blockade and reduced opioid tolerance increase overdose risk.

What side effects should I know about?

  • Nausea, headache, dizziness, fatigue, abdominal symptoms or sleep difficulty.
  • Vivitrol can cause tenderness, itching or a lump at the injection site.

Tell your prescriber about effects that are persistent, troublesome, or interfere with daily life.

Which warning signs need help?

  • Slow or stopped breathing, inability to awaken or suspected opioid overdose requires emergency treatment.
  • Severe withdrawal after starting, yellow skin or eyes, dark urine or persistent abdominal pain need urgent assessment.
  • Progressive injection-site pain, dark skin, blistering or open wounds, or new breathing difficulty after Vivitrol need urgent help.
  • Report new depression or suicidal thoughts promptly. If you cannot stay safe, seek emergency care now.

What else should I know to stay safe?

  • Do not start with current opioid use, opioid dependence or withdrawal, a positive opioid screen, a failed naloxone challenge, or an allergy to the product. Starting or restarting needs clinical assessment: short-acting opioid dependence generally requires at least 7–10 opioid-free days, and withdrawal vulnerability can last up to two weeks after methadone or buprenorphine. Tests do not guarantee a safe start.
  • Opioid tolerance falls during treatment. Attempting to overpower the blockade, or using a previously tolerated opioid amount after treatment wears off or is interrupted, can be fatal. Discuss access to overdose-reversal medicine. Tell emergency, surgical, and dental clinicians about naltrexone because pain treatment may need specialist planning.
  • Vivitrol must be administered by a healthcare professional as a deep buttock-muscle injection, never into a vein or under the skin. Review injection suitability, bleeding risk, liver or kidney disease, mood, and other potentially liver-damaging medicines; an interruption needs opioid-exposure reassessment.
  • Pregnancy and breastfeeding need an individualized plan with an addiction-experienced clinician, considering untreated illness as well as exposure. Naltrexone and a breakdown product enter milk; infant information is limited. Selected uses are not established under age 18.

Urgent help and crisis support · Emergency & Crisis Resources (US)

What can help day to day?

  • Tell dentists, emergency clinicians, and surgical teams about naltrexone. It can block usual opioid pain medicines, so pain care may need advance planning.
  • After a treatment gap or when an injection wears off, a previously tolerated opioid amount can become fatal. Discuss access to an overdose-reversal medicine and never try to overpower the blockade.

How does it work?

Naltrexone blocks opioid receptors, receiving sites used by the body’s own opioid signals and by medicines and drugs such as morphine and heroin. It occupies these sites without producing the usual opioid effect. Blocking the body’s own opioid signals is also thought to contribute to its benefit in alcohol treatment, but the exact explanation is not fully understood.

Explore medication science

How was this medicine developed?

Oral naltrexone received U.S. approval in 1984. Vivitrol was approved in 2006 as a long-acting injection, reducing the need for daily tablets while creating a sustained period of opioid blockade. The two forms need different administration and missed-treatment plans.

How do I say the name?

Naltrexone: nal-TREX-ohn. Capital letters show the stressed syllable.

Medicine forms and official information

Match the full name, release type and route on your prescription. Different formulations need their own prescribing instructions; do not switch or substitute them yourself.

Sources and References

Sources support the U.S. products described here. Product instructions can differ; use the information supplied with your own medicine.

  1. Oral naltrexone hydrochloride: current generic prescribing information
  2. Vivitrol: current prescribing information
  3. Naltrexone tablets: patient information
  4. Naltrexone injection: patient information
  5. Revia oral naltrexone: FDA approval and discontinued product record
  6. Vivitrol: FDA approval and product record
  7. Vivitrol: FDA prescribing information, December 2025
  8. Naltrexone: Package Insert / Prescribing Information
  9. Naltrexone: DailyMed product labeling
  10. Generic naltrexone hydrochloride: FDA application record
  11. SAMHSA TIP 63: medications for opioid use disorder (2021 update)
  12. Acamprosate calcium: prescribing information

Giving medicine safely to children: family guide (PDF, 3 pages)

How information is checked

Was this article helpful?

Was this article helpful?

Sends your choice, article identifier, edition and optional issue to Psychiatry Atlas. No name, email or medical details are requested. Daily network codes help prevent spam; hosting may process technical information. This is not a promise of anonymity. Privacy details.

Enable JavaScript to send feedback.

Suggest a missing topic or describe a correction. Please keep personal medical information out of website feedback.

Back to top